Abstract
The natural course of Crohns disease is characterized by the progression from primarily inflammatory disease to a complicated stricturing or penetrating disease. These irreversible complications lead to repeated surgery and considerable disability. Therefore it may be argued that a window of opportunity for intensive treatment exists early in the disease course. Healing of the mucosa has been shown to be a strong predictor of improved outcome of Crohns disease on the long-term, in terms of disease control, hospitalizations, and surgery. Anti-tumor necrosis factor (TNF)-α therapy has shown to be a strong inducer of mucosal healing and it may be argued that early treatment with anti-TNFs and/or immunomodulators may be the preferable approach in selected patients. The main concern with such strategies is safety, especially the risk of lymphomas and infections. This paper aims to review the existing data regarding the benefits and disadvantages of inverting the classic step up therapeutic paradigm.
Keywords: Crohn's disease, top-down, step-up, tumor necrosis factor-α, immunomodulators, mucosal healing, course of disease, immunosuppression
Current Drug Targets
Title: Anti-TNF and Crohns Disease: When Should we Start?
Volume: 11 Issue: 2
Author(s): H. H. Fidder and D. W. Hommes
Affiliation:
Keywords: Crohn's disease, top-down, step-up, tumor necrosis factor-α, immunomodulators, mucosal healing, course of disease, immunosuppression
Abstract: The natural course of Crohns disease is characterized by the progression from primarily inflammatory disease to a complicated stricturing or penetrating disease. These irreversible complications lead to repeated surgery and considerable disability. Therefore it may be argued that a window of opportunity for intensive treatment exists early in the disease course. Healing of the mucosa has been shown to be a strong predictor of improved outcome of Crohns disease on the long-term, in terms of disease control, hospitalizations, and surgery. Anti-tumor necrosis factor (TNF)-α therapy has shown to be a strong inducer of mucosal healing and it may be argued that early treatment with anti-TNFs and/or immunomodulators may be the preferable approach in selected patients. The main concern with such strategies is safety, especially the risk of lymphomas and infections. This paper aims to review the existing data regarding the benefits and disadvantages of inverting the classic step up therapeutic paradigm.
Export Options
About this article
Cite this article as:
Fidder H. H. and Hommes W. D., Anti-TNF and Crohns Disease: When Should we Start?, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309993
DOI https://dx.doi.org/10.2174/138945010790309993 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Cytokine Network in HIV Infection
Current Molecular Medicine Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Functional and Structural Roles of GPI Moieties in Mammalian Plasma Membranes
Current Organic Chemistry Therapeutic Proteins: A to Z
Protein & Peptide Letters Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Radioimmunotherapy of Non-Hodgkins Lymphomas
Current Drug Targets Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy
Current Pharmaceutical Design Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects
Current Bioinformatics Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Current Cancer Drug Targets Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis Pgp and FLT3: Identification and Modulation of Two Proteins that Lead to Chemotherapy Resistance in Acute Myeloid Leukemia
Current Medicinal Chemistry Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders
Current HIV Research